Evidence map›Paper›PMID 33193865›Full record

ArticleAsian journal of pharmaceutical sciences2020

Oxidation-strengthened disulfide-bridged prodrug nanoplatforms with cascade facilitated drug release for synergetic photochemotherapy.

Bin Yang, Lin Wei, Yuequan Wang, Na Li, Bin Ji, Kaiyuan Wang, Xuanbo Zhang, Shenwu Zhang, Shuang Zhou, Xiaohui Yao and 6 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Bin YangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Lin WeiMinistry of Education, Heilongjiang University, Harbin 150500, China.
Yuequan WangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Na LiWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Bin JiDepartment of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang 110001, China.
Kaiyuan WangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Xuanbo ZhangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shenwu ZhangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shuang ZhouWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Xiaohui YaoWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Hang SongWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yusheng WuDepartment of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang 110001, China.
Haotian ZhangSchool of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
Qiming KanSchool of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
Tao JinMinistry of Education, Heilongjiang University, Harbin 150500, China.
Jin SunWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shenyang Pharmaceutical University · CNChina Medical University · CNHeilongjiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the major barriers in utilizing prodrug nanocarriers for cancer therapy is the slow release of parent drug in tumors. Tumor cells generally display the higher oxidative level than normal cells, and also displayed the heterogeneity in terms of redox homeostasis level. We previously found that the disulfide bond-linkage demonstrates surprising oxidation-sensitivity to form the hydrophilic sulfoxide and sulphone groups. Herein, we develop oxidation-strengthened prodrug nanosystem loaded with pyropheophorbide a (PPa) to achieve light-activatable cascade drug release and enhance therapeutic efficacy. The disulfide bond-driven prodrug nanosystems not only respond to the redox-heterogeneity in tumor, but also respond to the exogenous oxidant (singlet oxygen) elicited by photosensitizers. Once the prodrug nanoparticles (NPs) are activated under irradiation, they would undergo an oxidative self-strengthened process, resulting in a facilitated drug cascade release. The IC

Indexed as

Accurate therapyDisulfide bondProdrug nanoplatformPyropheophorbide aRedox-heterogeneity

Identifiers

PMID33193865
PMCPMC7610204
OpenAlexW2987805191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.